Signals Inbox·August 30, 2026·Biopharma

Who are the top startups curing baldness now?

Pelage Pharmaceuticals leads the baldness startup race today, followed by Amplifica and Hope Medicine, while OrganTech is pursuing the much harder prize: creating entirely new functional hair follicles.

Q1Are any startups actually close to curing baldness?

A few baldness startups are now close enough to take seriously, with Pelage Pharmaceuticals leading today, although nobody has yet shown a permanent cure for pattern hair loss.

The field looks very different from the endless "hair cloning is five years away" stories of the past. Pelage and Amplifica have already tested new follicle-reactivation approaches in people. Hope Medicine has completed a much larger Phase 2 trial of HMI-115. Epibiotech is currently recruiting patients for a trial of its own follicular-cell therapy. HairClone has moved its cell technology into early clinical testing. OrganTech, meanwhile, recently published another meaningful step toward reconstructing whole follicles.

These companies are solving different versions of baldness. Pelage, Amplifica and Hope Medicine are mostly trying to get miniaturized or dormant follicles growing properly again. Epibiotech and HairClone want to restore follicles using cells taken from healthy hair. OrganTech is working on the much harder problem of building functional replacement follicles.

Our ranking therefore depends on what we mean by "cure." Pelage currently has the best combination of human evidence, interesting biology and resources to reach a large trial. OrganTech is pursuing something much closer to a literal replacement for lost follicles, but its technology remains far earlier.

So yes, the baldness startup race is real now. The likely first breakthrough will probably make ordinary pattern baldness much more reversible before anyone can give a severely bald patient an unlimited new supply of follicles.

Q2What would actually count as a baldness cure?

For this article, a real baldness cure means restoring enough lasting hair that someone no longer needs to apply or take the same treatment every day indefinitely.

That definition immediately separates a cure from today's standard treatments. Finasteride can slow androgen-driven follicle miniaturization. Minoxidil can improve growth. Both can work well for some people, but their effect generally depends on continuing treatment. Hair transplantation provides permanent transplanted follicles, although surgeons remain limited by the amount of suitable donor hair available on the patient's scalp.

A treatment such as PP405 could potentially sit somewhere in between. If a short course woke dormant follicles and those follicles continued producing useful hair for a long period, many patients would reasonably experience that as a functional cure even though no new follicle had been manufactured.

The hardest version of baldness needs something more. A person with too few salvageable follicles would need new functional follicles, or at least cells capable of reconstructing them. That is where OrganTech and the longer-term ambitions of companies such as HairClone become important.

What would actually count as curing baldness?

Q3Why does the baldness startup race look much more serious now?

The baldness startup race looks much more serious today because several unrelated technologies have crossed from interesting biology into human testing at roughly the same time.

Pelage is testing a topical molecule that changes the metabolism of dormant hair-follicle stem cells. Amplifica uses naturally occurring signaling molecules to restart follicle growth. Hope Medicine blocks the prolactin receptor with an antibody. Epibiotech is injecting cultured dermal papilla cells from the patient's own follicles. These approaches are different enough that the industry no longer depends on one fashionable theory of why follicles stop producing useful hair.

Money has followed the clinical progress. Pelage raised $120 million in its latest major round, co-led by ARCH Venture Partners and GV. More recently, Amplifica closed an oversubscribed $26 million Series B with investors including Eli Lilly, shortly before adding veteran dermatology drug-development executive Hans Hofland as chief development officer. That sequence looks like a company preparing to move from a small first-in-human experiment toward a much heavier clinical-development program.

The regenerative side is moving too. Epibiotech's EPI-001 study is currently recruiting. HairClone has built a GMP cell-manufacturing operation in Guatemala and started clinical testing. OrganTech and RIKEN researchers recently reported that three populations of adult follicle-derived cells could reconstruct fully functional hair follicles in an in-vitro system.

None of those developments guarantees a successful drug. Put together, though, today's pipeline is much deeper than previous waves of baldness hype.

Q4Is Pelage Pharmaceuticals the baldness startup to beat right now?

Pelage Pharmaceuticals is currently the baldness startup to beat because PP405 has the best mix of a genuinely new mechanism, controlled human evidence and enough financing to push the program into large late-stage studies.

PP405 is a topical inhibitor of the mitochondrial pyruvate carrier. The science behind it comes from research into the metabolic switch that helps hair-follicle stem cells move from dormancy into active growth. In plain English, Pelage is trying to wake follicles that still exist but have stopped producing useful visible hair.

That makes PP405 particularly interesting for androgenetic alopecia. Research has shown that balding scalp can retain hair-follicle stem cells even after the visible hair has become extremely small or disappeared. Pelage is attempting to use that remaining biological machinery rather than fight DHT directly.

The company also has unusual financial firepower for a hair-loss biotech. Its $120 million Series B was co-led by ARCH and GV, two experienced life-sciences investors, after GV had already backed an earlier financing.

There is one reason to keep the enthusiasm under control. Pelage has repeatedly said it expects to move PP405 into late-stage studies during 2026, but its latest public program information still centers on the completed Phase 2a study. We have yet to see the sort of large registrational trial that would tell us how often PP405 produces cosmetically meaningful regrowth across ordinary patients.

For now, nobody else combines PP405's clinical head start, regenerative angle and financing quite as convincingly.

Q5How good is PP405 in humans so far?

PP405 looks genuinely promising in humans so far, especially for such a short treatment period, but Pelage's efficacy case still rests on a small exploratory dataset.

Pelage's randomized Phase 2a enrolled 78 men and women with androgenetic alopecia. Patients used PP405 or placebo once daily for four weeks. The main purpose of the trial was safety and pharmacokinetics rather than proving hair regrowth, which is important when interpreting the efficacy numbers.

The most interesting result came from men with more advanced hair loss. Four weeks after treatment had ended, 31% of PP405-treated men in that group had increased hair density by more than 20%, compared with 0% receiving placebo. Pelage also reported terminal hair appearing from follicular units where visible hair had previously been absent.

The timing makes the result unusual. Standard hair-loss therapies are normally judged after many months, while these patients had received PP405 for only four weeks. Seeing an effect continue after dosing stopped is one reason the drug has attracted so much attention.

We still need the average effect across patients, longer follow-up and a much larger sample. A therapy where one-third of selected patients respond strongly could still become valuable, but it would be very different from one that reliably restores substantial density for most people.

PP405 has comfortably cleared the "interesting experiment" bar. Predictable cosmetic transformation is another bar entirely.

Q6Could PP405 regrow hair on a completely bald scalp?

PP405 could potentially regrow hair in an area that looks bald if usable dormant follicles remain there, but Pelage has not shown that PP405 can manufacture follicles after the original follicular structure has been lost.

This distinction is easy to miss because a smooth-looking scalp does not necessarily mean every follicle has disappeared. During androgenetic alopecia, follicles progressively miniaturize. They produce thinner and shorter hairs until some become virtually invisible, while important stem-cell populations can remain.

That biological fact is the foundation of Pelage's approach. The company's early observation of terminal hairs appearing from previously inactive follicular units suggests PP405 may reach further into advanced hair loss than treatments that simply make already-growing hairs thicker.

There should still be a limit. Long-standing severe baldness can involve extreme miniaturization and changes to the surrounding tissue. PP405 requires something biologically useful to reactivate. Pelage has produced no evidence that its small molecule can create an entirely new follicular organ from scratch.

The practical opportunity remains huge even with that limitation. A treatment capable of recovering useful density from follicles that currently appear dead could help people who today move from medication to transplantation because their remaining visible hair has become too sparse.

Someone with virtually no recoverable follicles is a different problem. That's where OrganTech and the cell-therapy companies enter the picture.

Q7Is Amplifica a real threat to Pelage?

Amplifica is currently Pelage's strongest private challenger, and the company's latest financing and hiring suggest it is preparing for a much bigger clinical push.

AMP-303 uses an injectable approach. In Amplifica's first-in-human trial, each participant received AMP-303 on one side of the frontal-temporal scalp and placebo on the other. That paired design is useful because hair growth varies enormously from person to person, so comparing two areas on the same patient removes some of that noise.

Amplifica reported that a statistically significant proportion of participants achieved more than a 15% increase in non-vellus hair count versus the placebo-treated area after 60 days. A significant proportion still had an improvement above 10% after 150 days. The persistence is particularly interesting because AMP-303 was given as a treatment cycle rather than as a daily drug used for months.

The company has lately strengthened the business around that science. Amplifica raised $26 million in an oversubscribed Series B led by Tasso Partners with Eli Lilly participating, then brought in Hans Hofland, who has spent decades developing dermatology drugs, as chief development officer.

The main weakness is straightforward: Amplifica still has not publicly given us enough data to calculate the average placebo-adjusted benefit across the whole study population. We know meaningful numbers of patients crossed certain response thresholds, but we cannot yet see the full response distribution.

That keeps Amplifica behind Pelage today. A larger controlled study with a clear average effect could narrow the gap quickly.

Q8Is Hope Medicine being overlooked in the baldness race?

Hope Medicine is probably the most overlooked serious company in baldness today because HMI-115 has already completed a 192-person randomized Phase 2 trial, yet the detailed hair-growth results remain unavailable.

HMI-115 is a monoclonal antibody that blocks the prolactin receptor. Hope Medicine licensed the molecule from Bayer and has developed it for several conditions linked to prolactin signaling, including androgenetic alopecia.

The first small human hair-loss study produced a result worth following. In an open-label Australian Phase Ib trial, 12 male participants gained an average of 14 non-vellus hairs per square centimetre after 24 weeks. Four women were also enrolled, although the company highlighted the male efficacy result.

Hope Medicine then moved into a much stronger test. ClinicalTrials.gov records a randomized, double-blind, placebo-controlled Phase 2 study involving 192 men across several dosing arms. The study is marked completed, while the registry currently shows no posted results.

That missing dataset now dominates our view of HMI-115. Hope Medicine's current pipeline still places androgenetic alopecia in Phase 2, so the hair-loss program has not disappeared. The same antibody has also progressed further in Hope Medicine's endometriosis program, showing that the company remains actively developing HMI-115 as a drug.

If the 192-person alopecia study reproduced a strong placebo-adjusted benefit, Hope Medicine could jump near the top of this ranking. Until we can actually see those numbers, placing it above Pelage or Amplifica would require too much guesswork.

Q9Is Epibiotech the most serious hair-cell therapy startup right now?

Epibiotech currently has the clearest conventional clinical program among startups trying to treat pattern baldness with a patient's own follicular cells.

Its lead program, EPI-001, uses autologous dermal papilla cells. These cells sit at the bottom of the hair follicle and help regulate whether the follicle grows, rests and produces a thick terminal hair. In androgenetic alopecia, changes to this cellular environment contribute to progressive miniaturization.

Epibiotech takes follicles from the patient, cultures the relevant cells and injects them into thinning scalp. The objective is to restore the biological support needed for weak follicles to produce better hair.

What makes Epibiotech particularly interesting now is the structure of its clinical study. The EPI-001 Phase I/IIa trial is currently listed as recruiting on ClinicalTrials.gov and is designed to enroll roughly 42 patients. The early part focuses on dose and safety, followed by a randomized portion comparing EPI-001 with placebo. Planned outcomes include hair counts, hair diameter, standardized photography and both investigator and patient assessments.

Forty-two patients will not settle whether dermal papilla cell therapy works. It is enough, however, to start answering a question that has frustrated hair-regeneration researchers for decades: can expanded human follicular cells retain enough of their original function to produce a measurable improvement when put back into a balding scalp?

Among the cell companies, Epibiotech currently gives us the cleanest way to find out.

Q10Can hair-cell therapy really create brand-new follicles?

Today's hair-cell therapies are much closer to rejuvenating weak follicles than manufacturing thousands of brand-new ones, and nobody has clinically proved large-scale follicle creation in humans yet.

The attraction of dermal papilla cells is easy to understand. These cells help organize follicle development and control the hair cycle. Take cells from healthy permanent hair, grow many more of them in a laboratory and theoretically the patient's limited donor supply becomes much less important.

The difficulty appears during the "grow many more" step. Human dermal papilla cells tend to lose part of their hair-inducing behavior when they are repeatedly expanded outside their normal follicular environment. HairClone openly discusses this problem in its own technical material and says useful follicle neogenesis will probably require rebuilding organized hair rudiments before implantation rather than simply injecting huge numbers of loose cells.

That explains a lot about the strategies now being tested. Epibiotech and HairClone are initially aiming at rejuvenating miniaturized follicles with expanded cells. OrganTech is tackling the more ambitious engineering problem of assembling the different cell populations into a new follicular structure.

If Epibiotech or HairClone can consistently turn tiny weak hairs back into thick terminal hairs, that would already be a major treatment. Creating entirely new follicles everywhere on a bald scalp remains another level harder.

Q11Is OrganTech closest to actual hair cloning?

OrganTech is currently the company closest to literal hair cloning at the scientific level because its work aims to reconstruct complete functional follicles from expanded adult follicular cells.

The Japanese company is closely tied to regenerative-organ research led by Takashi Tsuji, whose former RIKEN laboratory spent years studying how epithelial and mesenchymal cells interact to build hair follicles.

The newest OrganTech-RIKEN work pushes that approach forward. Researchers identified a third supporting mesenchymal population that appears to be needed alongside the better-known epithelial and dermal papilla components. Using three adult hair-follicle-derived cell populations, the team reconstructed follicular structures that could form functional follicles and produce hair in an in-vitro culture system.

That is a very different scientific objective from giving an existing follicle a stronger growth signal. If OrganTech can eventually turn a small number of donor follicles into a large supply of transplantable follicular units, the finite donor-hair problem that limits hair transplantation could largely disappear.

Human translation is still the enormous missing piece. OrganTech needs to show that reconstructed follicles can be produced reliably, implanted safely, grow in the right direction, make cosmetically normal hair and keep cycling over many years.

OrganTech is nowhere near Pelage in clinical proof. But for someone asking which startup is working on the closest thing to "make me new follicles," this is the one to watch.

Q12What is HairClone actually testing now?

HairClone has moved beyond follicle banking and is now starting clinical testing of its autologous follicular-cell treatment in Guatemala.

HairClone's basic idea is to remove around 100 to 120 healthy follicles from areas resistant to androgenetic hair loss, preserve them, isolate dermal papilla cells when treatment is needed, expand those cells dramatically in the laboratory and inject them into miniaturizing areas of the scalp.

The initial treatment is aimed at rejuvenation. HairClone hopes extra healthy dermal papilla cells can make shrinking follicles produce thicker terminal hairs again. Creating entirely new follicles remains part of its longer-term research rather than what the company says it can currently deliver.

The company has recently built and validated a GMP cell-manufacturing facility inside a private hospital in Guatemala City. HairClone says clinical testing is underway with the Schambach Hair Clinic and that an initial group of volunteers has been selected for autologous follicle-cell injections.

We should be precise about what "clinical testing" means here. HairClone says its early testing does not use a fixed protocol, allowing the team to change parts of the process as it learns from patients. That can be useful for developing a complicated cell therapy, but the eventual efficacy evidence will be harder to interpret than data from a blinded randomized trial.

HairClone is considerably more tangible today than it was when its main public product was follicle banking. Patient results are the next thing that matters.

Q13Why isn't Veradermics number one if its hair-growth data are much stronger?

Veradermics has much stronger clinical hair-growth evidence than any startup in this ranking, but it is now a public company and its lead treatment is an improved minoxidil formulation rather than a new way of regenerating follicles.

VDPHL01 is an extended-release oral version of minoxidil designed to maintain drug exposure while avoiding some of the high peaks seen with immediate-release oral minoxidil. Scientifically, that is far less radical than waking stem cells or creating new follicles. Clinically, it is far ahead.

In Veradermics' randomized Study 302, more than 500 men with pattern hair loss received VDPHL01 or placebo. After six months, mean non-vellus hair counts increased by 30.3 hairs per square centimetre with once-daily dosing and 33.0 with twice-daily dosing, versus 7.3 with placebo. The improvement was already statistically significant at the first measured point after two months.

The development program has kept moving. More than 1,000 men have been enrolled across Studies 302 and 304, and the company's female Phase 2/3 Study 306 has now finished enrolling 556 women. Veradermics has also reported encouraging open-label Phase 2 data in women.

Those numbers give us a useful reality check. Pelage's 78-person study and Amplifica's small first-in-human experiment are early compared with a registrational program of this scale.

Veradermics may well reach patients sooner. We keep it outside the startup ranking because the question here is who is building the next generation of baldness treatments, particularly approaches that could change what damaged follicles are capable of doing.

Q14Which famous baldness startups have already fallen out of the race?

Stemson Therapeutics and dNovo should now come off any current list of leading baldness startups, despite both having been among the most exciting names in hair regeneration a few years ago.

Stemson is the clearest example of why old hair-cloning lists age badly. The company was developing induced-pluripotent-stem-cell technology designed to generate completely new follicles. In early 2024 it announced that engineered follicular units had produced human hair follicles in humanized mice and licensed additional hair-regeneration technology from Aderans.

The company then shut down. Former CEO Geoff Hamilton has publicly explained that Stemson closed after failing to raise the large amount of funding required to move its cell therapy into clinical trials. The technology may eventually reappear elsewhere, but Stemson itself no longer belongs in a ranking of active startups.

dNovo had an equally ambitious idea: directly reprogram ordinary patient cells into hair-producing cells. The company generated enormous attention because it was explicitly trying to create new hair rather than preserve existing follicles. Y Combinator now marks dNovo as inactive.

These two disappearances are useful context for OrganTech, Epibiotech and HairClone. Hair regeneration is technically hard and extremely expensive to commercialize. A beautiful mouse result or a clever cell-reprogramming platform can still die before reaching a single meaningful human efficacy trial.

That's why human evidence and current company activity count for much more here than old promises.

Q15Which baldness startups are closest to a new treatment, and which are closest to a true cure?

Pelage and Amplifica are currently closest to a new regenerative-style treatment, while OrganTech is pursuing the approach closest to creating a true replacement supply of hair follicles.

Those races will probably finish years apart.

Pelage can potentially change the market without solving follicle manufacturing. If PP405 reliably wakes enough dormant follicles after limited treatment, a large group of people with ordinary androgenetic alopecia could regain useful coverage without needing new follicles.

Amplifica is chasing a similar commercial opportunity with injections that may require relatively infrequent treatment. Hope Medicine could also become a serious drug competitor if its completed Phase 2 study eventually produces convincing numbers.

Epibiotech and HairClone move one level deeper into the biology by putting expanded follicular cells back into the patient. Their near-term goal is still mostly rejuvenation rather than producing thousands of new follicles.

OrganTech faces the longest road but has the biggest theoretical ceiling. Manufacturing functional follicles would make treatment possible even when too little useful follicular machinery remains to wake up.

The first company that transforms baldness treatment is therefore unlikely to be the company that ultimately solves every form of baldness. Today, Pelage has the clearer path to changing common pattern hair loss. OrganTech is pursuing the more complete biological answer.

Q16So who are the top startups curing baldness now?

Pelage Pharmaceuticals is the top baldness startup today, with Amplifica the strongest challenger and OrganTech the company we would watch most closely for a future literal hair-cloning breakthrough.

We rank Pelage first because PP405 already has controlled human evidence, a genuinely different mechanism and the financial backing needed for expensive late-stage trials. The evidence remains early, but the pieces fit together better than they do for any other private company.

Amplifica comes second. AMP-303 has already produced a controlled human hair-growth effect, and the company has lately raised fresh money and added experienced drug-development leadership. A larger trial with transparent average hair-count data could make this a much closer race.

Hope Medicine comes third. HMI-115 has been tested in far more Phase 2 participants than PP405, but the absence of published results from that 192-person study is too important to ignore.

Epibiotech ranks fourth because EPI-001 is giving dermal papilla cell therapy a proper randomized clinical test. OrganTech follows in fifth overall despite having arguably the most ambitious technology, since fully engineered follicles are still preclinical. HairClone ranks sixth as its autologous cell program enters early human testing without comparable controlled efficacy data yet.

The final judgment is fairly clear. Nobody is curing baldness today in the strict sense of reliably restoring permanent hair to anyone who has lost it. Pelage currently leads the much nearer race to make common pattern baldness substantially reversible. OrganTech is pursuing the technology that could eventually handle cases where there are simply not enough useful follicles left to reactivate.

Top startups trying to cure baldness now